Skip to main content
Premium Trial:

Request an Annual Quote

Courtagen Life Sciences, Certainty Health Collaborate on Neurological Disorders

NEW YORK (GenomeWeb) – Neurology-focused testing and informatics firm Courtagen Life Sciences announced a partnership agreement with Scottsdale, Arizona-based Certainty Health.

Certainty Health said in a statement that it is developing a mobile device-based data-sharing platform for precision medicine to provide actionable molecular information about neurological diseases, diagnostics, and treatments.

Under the terms of the agreement, Woburn, Massachusetts-based Courtagen has gained exclusive access to Certainty Health's platform for neurological diseases. The firms will work together to import Courtagen's data into Certainty Health's system.

Financial and other terms of the deal were not disclosed.

"We are learning that many diseases like epilepsy, developmental delay, and autism are not single, common diseases, but really collections of diseases, some common, some quite rare," Courtagen President and COO Brendan McKernan said in a statement. "It's impossible for physicians to become experts in all of these rare diseases, and difficult to diagnose without genetic testing due to the overlapping nature of the symptoms, but a collaborative ecosystem, like the one we're building with Certainty Health, will enable physicians to benefit from the group knowledge of their colleagues around the world and entirety of our test data."

Courtagen added in a statement that the deal will aid its pharmaceutical customers, as well as physicians. It's the latest partnership for the company — in September, Courtagen partnered with Astellas Pharma to study mitochondrial disease and last year inked distribution deals for genetic tests in Israel and Thailand.